Tysabri and Progressive Multifocal Leukoencephalopathy: What Illinois Patients Should Know
Latest update (2026-07)
Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Information to Occupational and Legal Concerns
If you or a loved one is taking Tysabri for multiple sclerosis or Crohn's disease, you may be concerned about the rare but serious risk of progressive multifocal leukoencephalopathy (PML). Decades of pharmacovigilance have established a clear link between this biologic therapy and PML, particularly in patients with certain risk factors. This page reviews the evidence on PML onset timing, monitoring guidelines, and what the science says about risk in Illinois.
Medical Evidence and Risk Factors for Tysabri-Associated PML
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Illinois who have developed PML after Tysabri treatment, understanding the medical evidence and legal time limits is critical. PML is an opportunistic viral infection of the brain caused by the JC virus that typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information for Tysabri includes a boxed warning stating that the drug increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and vision changes. In the FDA Adverse Event Reporting System (FAERS), the most frequently reported adverse events for Tysabri include fatigue, multiple sclerosis relapse, headache, gait disturbance, memory impairment, balance disorder, and cognitive disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these symptoms can overlap with multiple sclerosis itself, any new or worsening neurological symptoms in a Tysabri-treated patient should prompt immediate evaluation for PML. The prescribing information instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Mechanistic Pathways and Adequacy of Warnings
The mechanistic link between Tysabri and PML involves the drug's mechanism of action. Tysabri is an alpha-4 integrin antagonist that prevents immune cells from crossing the blood-brain barrier. This reduces inflammation in the central nervous system but also impairs normal immune surveillance. The JC virus, which is latent in many individuals, can reactivate and cause PML when immune control is compromised. The presence of anti-JCV antibodies indicates prior exposure to the virus and is a marker of increased risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Longer treatment duration, especially beyond two years, further increases the risk because prolonged immune suppression in the brain allows the virus to replicate unchecked. The boxed warning on Tysabri clearly states that the drug increases the risk of PML and that it usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning also identifies the three known risk factors and notes that these should be considered in the context of expected benefit. Additionally, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, which is designed to ensure that patients are monitored for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise about whether the risks were adequately communicated to patients and whether healthcare providers properly assessed individual risk factors before prescribing.
Statute of Limitations for Tysabri Claims in Illinois
For individuals in Illinois who have developed PML after Tysabri treatment, the statute of limitations for filing a personal injury lawsuit is generally two years from the date the injury was discovered or should have been discovered. This is governed by Illinois law (735 ILCS 5/13-202). The 'discovery rule' means that the clock starts when the patient knew or reasonably should have known that the injury was caused by Tysabri. For PML, this may be at the time of diagnosis, which can be delayed because symptoms may initially mimic multiple sclerosis relapse. It is important to consult with an attorney promptly to determine the specific filing deadline in each case, as delays can bar recovery. Patients affected by Tysabri-associated PML may seek legal representation to pursue claims for inadequate warnings or failure to monitor. An attorney can review medical records to determine whether the prescribing physician followed the recommended risk mitigation strategies, such as testing for anti-JCV antibodies and monitoring for symptoms. The timeline between exposure and documented harm is critical: PML typically occurs after months to years of Tysabri treatment, and the duration of therapy is a known risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). An attorney can help establish when the injury occurred and when it was discovered, which is essential for statute of limitations calculations.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Tysabri-related PML claims in Illinois?
In Illinois, the statute of limitations for personal injury claims, including those related to Tysabri-associated PML, is generally two years from the date the injury was discovered or should have been discovered. This is governed by Illinois law (735 ILCS 5/13-202). The discovery rule applies, meaning the clock starts when the patient knew or reasonably should have known that the injury was caused by Tysabri. Prompt legal consultation is essential to preserve the right to seek compensation.
What are the known risk factors for developing PML while on Tysabri?
Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment. The prescribing information includes a boxed warning about the increased risk of PML.
What symptoms should prompt immediate evaluation for PML in Tysabri patients?
Any new or worsening neurological symptoms, such as progressive weakness, gait disturbance, cognitive impairment, vision changes, memory impairment, balance disorder, or cognitive disorder, should prompt immediate evaluation for PML. The prescribing information instructs healthcare professionals to withhold Tysabri immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.
Free Case & Eligibility Review
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.